With the appointment of industry veteran, John
Frijters, a distribution partnership with Bandagist Jan Nielsen,
and assistance from The Robert Jones and Agnes Hunt Orthopaedic
Hospital NHS Foundation Trust
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the
“Company”), a wearable medical robotics company, today announced
continued momentum across Europe with the appointment of John
Frijters as Business Development Manager for EU, a distributor
agreement with Bandagist Jan Nielsen to deliver MyoPro to patients
across Denmark and the first screening day in the United
Kingdom.
"We estimate the number of patients in the EU who could benefit
from MyoPro is well over a million people,” says Jon Naft, Myomo VP
and General Manager. “We believe that the European market will
be an important part of the MyoPro business in the long term, so we
are establishing these strategic footholds."
Paul R. Gudonis, Chairman and CEO of Myomo, said, “This
announcement reaffirms Myomo’s commitment to helping restore
function in the arms and hands of individuals who are suffering
from the effects of a neuromuscular disease or injury. We are
looking forward to providing more individuals a chance to improve
their quality of life.”
Background on John Frijters
Myomo announces the appointment of John Frijters as Business
Development Manager for Europe. John will be responsible for
managing Myomo’s relationship with existing distribution partners
and establishing additional distributors throughout the EU.
Prior to joining Myomo, John Frijters worked for ReWalk Robotics
in the position of V.P. Sales & Business Development Europe
from 2010 to 2018. Before ReWalk, John served as V.P. of
Global Sales and Marketing at Stryker-Berchtold, and spent most of
his professional career in various roles with Ottobock, a
manufacturer and supplier of a range of healthcare products
including prosthetics, orthotics, rehabilitation technology and
mobility products.
“I am honored to join the Myomo team as Business Development
Manager,” said John Frijters. “Throughout my career, I’ve enjoyed
working with multi-national teams in the field of non-invasive
medical devices and medical products, and I am looking forward to
bringing my knowledge, network and expertise to Myomo.”
Distribution Contract
Bandagist Jan Nielsen and Myomo have signed a distribution
contract to help bring MyoPro to patients in the Nordic region.
Headquartered in Copenhagen Denmark, Bandagist Jan Nielsen was
founded and is currently owned by Jan Nielsen (CPO). Nielsen has a
team of bandagists, physiotherapists, specialized technicians, (CO,
CPO’s) and shop assistants that manage the patient care needs on
orthosis and prosthesis and other medical aids. The team also
offers patients in-home visits.
“Myomo's leading technology is now available in Denmark, and the
MyoPro completes our offer to the many Danish people that lost
the capability to use their hand and arm following a stroke or a
brachial plexus injury,” said Jan Nielsen, CPO and CEO of Bandagist
Jan Nielsen. “Myomo's products together with Bandagist Jan Nielsen
A/S presents a great solution for the many Danish people that need
this innovative orthotic technology."
The company employs 45 employees at two locations in Kopenhagen
(Frederiksborggade and Sundholmsvej) and has clinic sessions at
satellite clinics in Sjæland and Føun.
Bandagist Jan Nielsen and Myomo attended the 11th Nordic
Prosthetist and Orthotist Conference in Copenhagen September 6-8,
2018.
First Screening Day in the United Kingdom
Myomo conducted the first ever MyoPro free screening day in the
United Kingdom with Robert Jones and Agnes Hunt Orthopaedic
Hospital NHS Foundation Trust and Hobbs Rehabilitation. Held on
September 4, 2018, the screenings gave potential users a convenient
chance to be evaluated by clinical specialists to determine if the
MyoPro might help them overcome upper-limb paralysis caused by
stroke, brachial plexus injury or other neuromuscular disease or
injury. Ten attended and eight were qualified. Myomo has seen good
success with screening days across the United States and is
continuing to educate and assist more individuals, families,
physicians, and therapists about the benefit of the MyoPro
myoelectric orthosis.
"We have spent ten years looking for a myoelectric elbow brace
to restore arm and hand function to our paralyzed patients and have
finally found it in MyoPro” said Mr. Simon Pickard, Consultant
Orthopaedic Surgeon at Robert Jones & Agnes Hunt Orthopaedic
& District Hospital NHS Trust. “These screening days make it
very convenient for clinicians to evaluate patients and prescribe
the device."
About Myomo
Myomo, Inc. is a wearable medical robotics company that offers
expanded mobility for those suffering from neurological disorders
and upper limb paralysis. Myomo develops and markets the MyoPro
product line. MyoPro is a powered upper limb orthosis designed to
support the arm and restore function to the weakened or paralyzed
arms of patients suffering from CVA stroke, brachial plexus injury,
traumatic brain or spinal cord injury, ALS or other neuromuscular
disease or injury. It is currently the only marketed device that,
sensing a patient’s own EMG signals through non-invasive sensors on
the arm, can restore an individual’s ability to perform activities
of daily living, including feeding themselves, carrying objects and
doing household tasks. Many are able to return to work, live
independently and reduce their cost of care. Myomo is headquartered
in Cambridge, Massachusetts, with sales and clinical professionals
across the U.S. and distribution partners in Europe. For more
information, please visit www.myomo.com.
Forward Looking Statements
This press release contains forward-looking statements regarding
the Company's future business expectations including with respect
to the Company’s plans and expectations for the European market,
which are subject to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are only predictions and may differ materially from
actual results due to a variety of factors. Our actual results
could differ materially from those anticipated in these forward
looking statements for many reasons, including, without limitation,
risks related to regulatory approval and market acceptance of our
products, and the other risk factors contained in our filings made
with the Securities and Exchange Commission. More information about
factors that potentially could affect Myomo's financial results is
included in Myomo's filings with the Securities and Exchange
Commission. The Company cautions readers not to place undue
reliance on any such forward-looking statements, which speak only
as of the date made. The Company disclaims any obligation
subsequently to revise any forward-looking statements to reflect
events or circumstances after the date of such statements or to
reflect the occurrence of anticipated or unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180912005211/en/
Investor Relations:PCG AdvisoryVivian Cervantes,
646-863-6274vivian@pcgadvisory.comorPublic Relations:Matter
CommunicationsMeredith Krim, 617-874-5203myomo@matternow.com
Myomo (AMEX:MYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myomo (AMEX:MYO)
Historical Stock Chart
From Apr 2023 to Apr 2024